Examples of using Immatics in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Immatics launches Phase 2 study on cancer vaccine IMA901.
Regulatory approval to start our second clinical study in our ACTengine®-based celltherapy program is a significant step for Immatics.
Immatics and MD Anderson announce launch of Immatics US, Inc.
ACTolog™ involves selecting, enriching and the ex-vivo expansion of a patient'sendogenous T cells specifically recognizing Immatics' XPRESIDENT® targets.
Immatics wins 2012 TiE50 Award immatics chosen as a leading company in the life….
We definitively hope that this potential immunotherapeutic from immatics represents an alternative treatment method for our patients who suffer from renal cell cancer.
Immatics GmbH from Tübingen pulled in 54 million euros to develop immune therapies against a variety of tumours.
Idinvest Partners on investment in clean tech company; Movilitas Holding on sale of Movilitas Consulting;MIG funds on financing rounds for Immatics, Ganymed and Suppremol.
Paul Higham, CEO of immatics, said:"I am delighted to welcome Peter as our new Chairman.
ATS Beteiligungsverwaltung, the holding arm management from the Strüngmann brothers, provided the fresh funds at Ganymed;the Strüngmanns were active again at immatics alongside Dievini Hopp Biotech Holding from SAP founder Dietmar Hopp.
Immatics has also gained access to various technologies developed or in-licensed by MD Anderson.
Quality, development and market chances of the first product candidates of immatics convinced also us”, say Dr. Friedrich von Bohlen and Halbach of the Heidelberger Dievini advisors into health sciences GmbH.
Immatics will use this funding to complete the current phase 3 trial with its lead cancer vaccine IMA901 in patients with renal cell carcinoma RCC.
We see ourselves confirmed in the fact that immatics a prominent platform technology offers and has therefore again invested”, says Professor Erich mud, general partner with Wellington of partner.
Immatics' proprietary technology for the identification of tumor-associated peptides(TUMAPs) enables the development of novel anti-cancer vaccines for multiple cancer indications.
We are delighted to join forces with Immatics, a world leader in discovering truly novel cancer targets that would be otherwise inaccessible for antibody-based therapies.
Immatics is currently developing two multi-TUMAP products in clinical phase II studies- IMA901 for the treatment of renal cell carcinoma(RCC) and IMA910 for the treatment of colorectal carcinoma CRC.
We're extremely pleased that our collaboration with immatics has yielded positive phase 1 data with IMA950 and that through our Clinical Development Partnerships initiative we have been able to ensure it has the potential to reach patients sooner.
Immatics has been working for the last 15 years to gain a broad and in-depth understanding of the immunopeptidome of tumor and normal tissue cells,” said Harpreet Singh, CEO of Immatics US, Inc.
The product candidates of immatics are based on tumor-associated Peptiden so mentioned(TUMAPs), which stimulate the immune system against cancer cells.
This year immatics is to begin the clinical development of initial product candidates for treating renal cell cancer, which affects more than 100,000 people in industrial nations annually.
In parallel with the clinical development of IMA942 by Roche, immatics will conduct research on behalf of Roche using its unique XPRESIDENT® technology platform to identify novel and relevant TUMAP candidates for the development of cancer vaccines and other compounds targeting cancer peptide antigens, primarily in gastric.
Immatics and Roche sign cancer vaccine and immunotherapy collaboration Collaboration spans the discovery, development and commercialization of cancer vaccines and other cancer immunotherapies in gastric, lung and prostate cancer.
The clinical trial immatics and BioNTech will jointly take this actively personalized approach to immunotherapy into clinical development.
Immatics has paid CRT an undisclosed licensing fee for exclusive rights to the phase 1 clinical trial data and, provided IMA950 is successfully developed and commercialised, will pay further development milestones and downstream royalties.
This new chapter at Immatics is the first time that the three major venture capital investors in the German biotechnology industry have joined forces in a single company.
That immatics the new financing round in this order of magnitude locked, underlines, says the increasing meaning of biotechnological products also from the view of important decision makers from the industry” Dr. Klaus oak mountain, managing director of the BioRegio STAR management GmbH.
We are approaching a crucial period at immatics, and Peter's experience and track record in successfully developing biopharmaceutical companies will be invaluable, as we seek to produce a step-change in the treatment of cancer and maximize returns to our investors.
I am delighted to be joining immatics at such an exciting time and look forward to making a significant contribution to the successful implementation of the Company's corporate strategy, which is expected to deliver significant shareholder value and much improved treatment options for cancer patients.
Under the terms of the agreement, immatics will receive an upfront payment of $17 million and committed research funding plus potential milestone payments that could reach values in excess of $1 billion and royalties across three cancer indications, based on sales of the cancer vaccines and immunotherapies resulting from this agreement.